Amphista Therapeutics
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Biocity Bo'ness Newhouse Rd, Airdrie, No...Website
www.amphista.comRevenue
$16.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Amphista Therapeutics
Amphista Therapeutics was founded in 2017 and is a biopharmaceutical company creating first-in-class therapeutics that help harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amphista Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Amphista Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Amphista Therapeutics has new funding data
Amphista Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Amphista Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Amphista Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Amphista Therapeutics
Earning: See what the market has to say on Amphista Therapeutics recently announced quarterly report
Click to see if Amphista Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Amphista Therapeutics
Find more new buyers
Compare Similar Companies to Amphista Therapeutics
Compare insights from companies similar to Amphista Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Amphista Therapeutics
$16.1M
51-200
Private
$60.5M
2017
N/A
Company Profile Activity
Activity Insights
Amphista Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amphista Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amphista Therapeutics.
Amphista Therapeutics financials insights
Gather financial insights about Amphista Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$7.5M
2022
Series B
$53M
Amphista Therapeutics Tech Stack
A closer look at the technologies used by Amphista Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
Executive Moves, Promotion, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Amphista Therapeutics News & Media
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
Cambridge, UK, 24th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new pre-clinical data on its orally bioavailable SMARCA2 and TEAD Targeted Glue™ programs at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, US, and publication in bioRxiv of the optimization of early TEAD Targeted Glues™.Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
Cambridge, UK, 21st April 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announced the first public disclosure of the chemical structure of its lead Targeted Glue™ AMX-883, a novel DCAF16-dependent protein degrader of BRD9, during the New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California yesterday.Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
Cambridge, UK, 21st April 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announced the first public disclosure of the chemical structure of its lead Targeted Glue™ AMX-883, a novel DCAF16-dependent protein degrader of BRD9, during the New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California yesterday.Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual meeting being held in San Diego on 17-22 April, including an invited presentation on the discovery of AMX-883, Amphista’s BRD9 clinical candidate, at the New Drugs on the Horizon: Part 3 session.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amphista Therapeutics
Sign Up For FreeTo access detailed company insights
Amphista Therapeutics was founded in 2017 and is a biopharmaceutical company creating first-in-class therapeutics that help harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.... Read More
